Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Medical Device PIC

Johnson & Johnson MedTech and CED Medical Sign Third Strategic Cooperation Agreement to Expand Neurointerventional Partnership Behind Qiangyida Stent

Fineline Cube Sep 1, 2026
Company Deals PIC

WestGene and CREATE Sign License Deal to Co‑Develop In Vivo CAR‑T Therapies

Fineline Cube Aug 31, 2026
Company Deals PIC

Simnova Closes nearly RMB 400 Million Series B to Advance CAR‑NK Candidate SNC103

Fineline Cube Aug 31, 2026
Company Deals PIC

Leaderna Therapeutics Closes Series A+ Led by Grand View Capital to Advance Oligonucleotide Pipeline

Fineline Cube Aug 31, 2026
Company Drug PIC

Eli Lilly Wins FDA Approval for Mounjaro Cardiovascular Risk Reduction in Type 2 Diabetes

Fineline Cube Aug 31, 2026
Company Deals Medical Device PIC

Johnson & Johnson MedTech and CED Medical Sign Third Strategic Cooperation Agreement to Expand Neurointerventional Partnership Behind Qiangyida Stent

Fineline Cube Sep 1, 2026
Policy / Regulatory

NMPA CDE Issues Draft Guideline to Reduce or Replace Animal Testing for Monoclonal Antibodies, Opening Public Comment

Fineline Cube Sep 1, 2026
Company Policy / Regulatory

Shanghai RAAS’s SR604 Enters NMPA CDE Rare Disease Encouragement Program for Hemophilia and Factor VII Deficiency Treatment

Fineline Cube Sep 1, 2026
Company Drug

Eisai and Biogen’s Leqembi Approved in Mexico for Early Alzheimer’s Disease Treatment

Fineline Cube Dec 5, 2024

Eisai Co., Ltd (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB) have announced that their co-developed...

Company

AstraZeneca Appoints Iskra Reic as EVP, International, Amid Leon Wang’s Investigation in China

Fineline Cube Dec 5, 2024

AstraZeneca (AZ, NASDAQ: AZN), a leading UK pharmaceutical company, has announced the appointment of Iskra...

Company Drug

Shanghai Escugen Receives NMPA Approval for Second Phase III Trial of ESG401 in TNBC

Fineline Cube Dec 5, 2024

Shanghai Escugen, a China-based biopharmaceutical company, has announced receiving the green light from the National...

Company Drug

Johnson & Johnson Submits sBLAs to FDA for Tremfya Indications in Pediatric Psoriasis and Arthritis

Fineline Cube Dec 5, 2024

Global healthcare giant Johnson & Johnson (J&J; NYSE: JNJ) has announced the submission of two...

Company Deals

GSK plc Expands Pipeline with Rgenta Therapeutics Partnership for RNA-Targeted Splice Modulators

Fineline Cube Dec 5, 2024

GSK plc (NYSE: GSK), a leading global pharmaceutical company, continues to bolster its pipeline through...

Company Drug

Merus N.V. Receives FDA Approval for Bizengri for NRG1+ Pancreatic and Lung Cancers

Fineline Cube Dec 5, 2024

Holland-based Merus N.V. (NASDAQ: MRUS) has announced that it has received FDA approval for its...

Company Drug

Ipsen’s Bylvay Receives NMPA Clearance for Treating Itching in PFIC Patients in China

Fineline Cube Dec 5, 2024

France-based Ipsen (EPA: IPN) has announced that it has received marketing clearance from the National...

Company Drug

Tasly Pharma Receives NMPA Approval for Generic Lioresal (Baclofen) Oral Solution

Fineline Cube Dec 5, 2024

China-based Tasly Pharma Co., Ltd (SHA: 600535) has announced that it has received marketing approval...

Company Drug

Humanwell Healthcare’s Recombinant Plasmid Hepatocyte Growth Factor Injection Accepted for NMPA Review

Fineline Cube Dec 5, 2024

China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) has announced that the National Medical Products...

Company Drug

Haisco Pharmaceutical’s HSK46575 Receives NMPA Approval for Prostate Cancer Clinical Trial

Fineline Cube Dec 5, 2024

China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced the receipt of clinical trial...

Company Drug

Sichuan Kelun-Biotech’s SKB500 Receives NMPA Clinical Clearance for Solid Tumor Treatment

Fineline Cube Dec 5, 2024

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd, (HKG: 6990), a leading biopharmaceutical company based in China, has...

Company Drug

Cinclus Pharma’s Linaprazan for GERD Receives NMPA Marketing Approval

Fineline Cube Dec 5, 2024

Sweden-based Cinclus Pharma has announced that it has received marketing approval from the National Medical...

Company

CSPC Pharmaceutical’s CRB-701 Earns FDA Fast Track Designation for Cervical Cancer Treatment

Fineline Cube Dec 5, 2024

China-based CSPC Pharmaceutical Group Co., Ltd (HKG: 1093) has announced that it has received Fast...

Company Medical Device

Sisram Medical’s Alma Harmony and Alma Hybrid Receive EU Medical Device Certification

Fineline Cube Dec 5, 2024

Sisram Medical Ltd (HKG: 1696), an Israel-based company and part of the Fosun Pharmaceutical Group...

Company Drug

Shanghai Henlius Biotech’s HLX11 Biosimilar Accepted for Review by China’s CDE

Fineline Cube Dec 5, 2024

Shanghai Henlius Biotech Inc. (HKG: 2696), a leading biopharmaceutical company based in China, has announced...

Company Deals

Wuhan Kaideweisi Biotechnology Secures Series B Funding for Gynecologic Oncology Expansion

Fineline Cube Dec 5, 2024

Wuhan Kaideweisi Biotechnology Co., Ltd, a specialist in gynecologic oncology in China, has reportedly raised...

Company Drug

Shanghai Henlius Biotech’s HLX22 Receives NMPA Approval for Phase II HER2-Targeted Study

Fineline Cube Dec 5, 2024

Shanghai Henlius Biotech Inc., (HKG: 2696), a leading biopharmaceutical company based in China, has announced...

Company Deals

Jiangsu Recbio Technology Secures Private Placement with Yangtze River Pharmaceutical for Vaccine Development

Fineline Cube Dec 5, 2024

China-based Jiangsu Recbio Technology Co., Ltd (HKG: 2179) has successfully placed 142 million shares through...

Company Deals

Hangzhou Chance Pharmaceuticals Partners with Yiling Pharmaceutical for Inhalation Powder Development

Fineline Cube Dec 5, 2024

China’s Hangzhou Chance Pharmaceuticals Co., Ltd., a specialist in lung drug delivery, has entered into...

Company Deals

GRIT Biotechnology and Vitalgen BioPharma Partner on CRISPR-AaCas12bMAX Cell Therapies

Fineline Cube Dec 5, 2024

China-based cell therapy specialists GRIT Biotechnology and Shanghai Vitalgen BioPharma Co., Ltd have entered into...

Posts pagination

1 … 301 302 303 … 714

Recent updates

  • NMPA CDE Issues Draft Guideline to Reduce or Replace Animal Testing for Monoclonal Antibodies, Opening Public Comment
  • Shanghai RAAS’s SR604 Enters NMPA CDE Rare Disease Encouragement Program for Hemophilia and Factor VII Deficiency Treatment
  • Eisai Launches LEQEMBI IQLIK Subcutaneous Auto-Injector for Early Alzheimer’s Disease in the United States
  • Trump Signs Nine New MFN Drug Pricing Agreements, Expanding Pharma Deals to 26 Companies Covering 89% of Branded Market
  • Laekna Doses First Patient in Phase I Study of LAE118 PI3Kα Inhibitor for Advanced Solid Tumors, Licensed to Vasque Bio for Up to USD 527 Million
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

NMPA CDE Issues Draft Guideline to Reduce or Replace Animal Testing for Monoclonal Antibodies, Opening Public Comment

Company Policy / Regulatory

Shanghai RAAS’s SR604 Enters NMPA CDE Rare Disease Encouragement Program for Hemophilia and Factor VII Deficiency Treatment

Company Drug

Eisai Launches LEQEMBI IQLIK Subcutaneous Auto-Injector for Early Alzheimer’s Disease in the United States

Policy / Regulatory

Trump Signs Nine New MFN Drug Pricing Agreements, Expanding Pharma Deals to 26 Companies Covering 89% of Branded Market

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2026 | Fineline Information & Technology | BlogData by Themeansar.